

Anti-IL-4R α (Dupilumab), Human IgG4 Antibody

rev 02/21

CATALOG NO.: A2148-100 (100 μ g)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a fully human IgG4 monoclonal antibody that targets IL-4R α and inhibits IL-4 and IL-13 signaling. Both IL-4 and IL-13 play an important role in Th-2 mediated immune response. Their inhibition leads to reduced Type 2 inflammation. The biosimilar was generated in CHO cells using recombinant DNA technology. The original monoclonal antibody received approval from the FDA for the treatment of atopic dermatitis and eczema. Additionally, this antibody received approval to treat patients aged 12 years and above, suffering from moderate-to-severe asthma, and moderate-to-severe eosinophilic asthma, or oral corticosteroid-dependent asthma.

ALTERNATE NAMES: CD124, IL4RA, IL-4RA, IL4R

ANTIBODY TYPE: Monoclonal

CONCENTRATION: Lot specific

HOST/ISOTYPE: Recombinant / IgG4, kappa

SOURCE: CHO cells

IMMUNOGEN: Human IL-4R α

CAS NUMBER: 1190264-60-8

PURIFICATION: Protein A purified

FORM: Liquid


FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human


STORAGE CONDITIONS: Store at -80°C. Avoid freeze/thaw cycles

APPLICATIONS AND USAGE: *In vitro* studies

This information is only intended as a guide. The optimal dilutions must be determined by the user



Direct ELISA shows that Anti-IL-4R α (Dupilumab), Human IgG4 Antibody can bind to immobilized human IL-4R. EC50 = 357.7 ng/ml



SDS-PAGE Analysis to assess purity and integrity of Anti-IL-4R α (Dupilumab), Human IgG4 Antibody

RELATED PRODUCTS:

Anti-IL-12 β (Ustekinumab), Human IgG1 Antibody (A2137)
 Anti-IL-6 receptor (Tocilizumab), Human IgG1 Antibody (A1447)
 Anti-IL-23 α (Guselkumab), Human IgG1 Antibody (A2147)
 Anti-TNF- α (Adalimumab), humanized Antibody (A1048)
 Anti-IgE (Omalizumab), Humanized Antibody (A2145)

FOR RESEARCH USE ONLY! Not to be used on humans.